Diagnosing A Healthy US FDA: The MRI Drug Safety Review
Executive Summary
Do MRI contrast agents cause debilitating chronic illnesses in some patients who receive them? A group of patient advocates firmly believes they do. FDA’s approach to addressing the risk via a public advisory committee shows the agency has found an effective way to handle the type of safety scare that could have paralyzed it a decade ago.
You may also be interested in...
Warning Label For Gadolinium Contrast Agents Gets US FDA Panel Backing
Advisory committee agrees that risks of gadolinium retention in the brain and other organs need further study; actor Chuck Norris' wife was among several patients who testified of devastating medical problems following administration of agents.
Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome
An FDA advisory committee review of quinolone antibiotic safety focused on a very old safety issue – but points to a new era in antibiotic development, and restricted use models.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.